SGLT2 Inhibition in Heart Failure with a Preserved Ejection Fraction — A Win against a Formidable Foe

Published on Aug 27, 2021in The New England Journal of Medicine74.699
· DOI :10.1056/NEJME2113008
Mark H. Drazner62
Estimated H-index: 62
(UTSW: University of Texas Southwestern Medical Center)
Sources
Abstract
More Evidence for SGLT2 Inhibitors in Heart Failure Mark Drazner comments on the findings of the EMPEROR-Preserved trial, which assessed the potential benefit of empagliflozin in patients with a pr...
📖 Papers frequently viewed together
20215.21Heart
6 Citations
References0
Newest
Cited By0
Newest